Peptide T

Peptide T is a synthetic octapeptide (sequence Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr) derived from the V2 region of the HIV-1 envelope glycoprotein gp120. It was discovered in 1986 by Candace Pert and Michael Ruff as a potential antiviral agent for AIDS therapy[1][3][7]. Its primary mechanism is to block the binding and infection of HIV strains that use the CCR5 receptor to enter cells by mimicking part of gp120 and interfering with its interaction with CD4+ lymphocytes[1][4][5]. In addition to its antiviral activity, peptide T has demonstrated anti-inflammatory effects and neuroprotective properties in preclinical studies. It has been investigated for improving cognitive performance in neuroAIDS subjects and as a potential treatment for psoriasis[4][6]. Modified analogs such as DAPTA (Dala1-peptide T-amide) have also been studied clinically. The drug remains investigational; it reached Phase II clinical trials primarily targeting cognitive impairment associated with HIV infection[2][3].

Other names

HIV Peptide TPeptide TPeptide T HIVDala1-peptide T-amideDala-1-peptide T-amideDala 1-peptide T-amide